Sulfadiazine
- Generic Name
- Sulfadiazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H10N4O2S
- CAS Number
- 68-35-9
- Unique Ingredient Identifier
- 0N7609K889
- Background
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
- Indication
For the treatment of rheumatic fever and meningococcal meningitis
- Associated Conditions
- Acute Otitis Media caused by Haemophilus Influenzae, Chancroid, Conjunctivitis, Inclusion, Encephalitis, Malaria caused by Plasmodium falciparum, Meningitis caused by Haemophilus influenzae, Meningococcal Meningitis, Nocardiosis, Trachoma, Urinary Tract Infection, Wound Infections, Recurrent Rheumatic fever
- Associated Therapies
- -
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 100
- Registration Number
- NCT00000794
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2009-05-14
- Target Recruit Count
- 600
- Registration Number
- NCT00004317
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath